

02-05-01


A



Express Mail Mailing Label No.: EL 587864173 US

Date of Deposit: February 2, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

  
Linda Fall

J1033 U.S. PTO  
09/776466  
02/02/01



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE  
UTILITY PATENT APPLICATION TRANSMITTAL LETTER

Box Patent Application  
Assistant Commissioner for Patents  
Washington, DC 20231

Sir:

Enclosed for filing is the utility patent application of Burton G. Christensen et al. for  
Glycopeptide Derivatives.

Applicant(s) hereby request(s) that the above-captioned application NOT BE PUBLISHED under 35 USC §122(b) and 37 CFR §1.211. The undersigned hereby certifies that the invention disclosed in this application has not and will not be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Applicant(s) suggest(s) Figure \_ for inclusion on the front page of the patent application publication and patent.

Also enclosed are:

\_ sheet(s) of drawings;

a claim for foreign priority under 35 USC §§119 and/or 365 is hereby made to \_ filed in \_ on \_;

a certified copy of the priority document;

General Authorization for Petitions for Extension of Time and Payment of Fees;

an Assignment document;

an Information Disclosure Statement;

a bibliographic data entry sheet;

other: \_\_\_\_\_

an [X] executed [ ] unexecuted declaration of the inventor(s)

Please amend the specification by inserting before the first line the sentence --This application claims priority under 35 USC §§119 and/or 365 to \_ filed on \_, the entire content of which is hereby incorporated by reference.--

Please amend the specification by inserting before the first line the sentence --This application is a continuation of International Application No. - filed on \_, which designates the United States.--

Small entity status is hereby claimed.

The filing fee has been calculated as follows [ ] and in accordance with the enclosed Preliminary Amendment:

CLAIMS					
	No. of Claims		Extra Claims	Rate	Fee
<b>Basic Application Fee</b>					<b>\$355 (201)</b>
Total Claims	26	Minus 20 =	6	x \$9 (203) =	54
Independent Claims	4	Minus 3 =	1	x \$40 (202) =	40
If multiple dependent claims are presented, add \$135 (204)					135
<b>Total Application Fee</b>					<b>584</b>
Add Assignment Recording Fee if Assignment document is enclosed					40
<b>TOTAL APPLICATION FEE DUE</b>					<b>624</b>

This application is being filed without a filing fee at this time.

Charge \$ 624 to Deposit Account No. 50-0344 for the fee due.

The Commissioner is hereby authorized to charge any appropriate fees under 37 CFR §§1.16, 1.17 and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account 50-0344. This paper is submitted in duplicate.

Please address all correspondence concerning the present application to:

David E. Boone  
 Advanced Medicine, Inc.  
 901 Gateway Boulevard  
 South San Francisco, CA 94080  
 650/808-6452

Respectfully submitted,

Date: February 2, 2001 By:   
 Jeffrey A. Hagenah  
 Registration No. 35,175

Express Mail Mailing Label No.: EL 587864173 US

Date of Deposit: February 2, 2001

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Washington, DC 20231.

Linda Fall  
Linda Fall

BE IT KNOWN that WE, Burton G. Christensen, resident of Alamo, California, citizen of the United States of America; J. Kevin Judice, resident of El Granada, California, citizen of the United States of America; and YongQi Mu, resident of Los Altos, California, citizen of the Peoples Republic of China; have invented new and useful improvements in

**GLYCOPEPTIDE DERIVATIVES**



**27038**

PATENT TRADEMARK OFFICE